DOI: 10.12890/2019_001131

Interstitial Lung Disease in a Patient Treated with Denosumab

Authors

  • Ana Campo Ruiz Department of Internal Medicine,Hospital of Laredo, Laredo, Spain
  • Miguel F Carrascosa Department of Internal Medicine,Hospital of Laredo, Laredo, Spain
  • Sergio Tapia Concha Department of Radiology, Hospital of Laredo, Laredo, Spain
  • Anibal Hernández Gil Department of Pulmonary Medicine, Hospital of Laredo, Spain
  • Juan García Rivero Department of Pulmonary Medicine, Hospital of Laredo, Spain

miguel.carrascosa@scsalud.es

Keywords

Interstitial lung disease, denosumab, osteoporosis

Abstract

Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significant interstitial lung disease likely related to denosumab.

View the entire article

Downloads

Published

2019-07-03

Issue

Vol. 6 No. 7 (2019)

How to Cite

1.
Ruiz AC, Carrascosa MF, Concha ST, Gil AH, Rivero JG. Interstitial Lung Disease in a Patient Treated with Denosumab. EJCRIM [Internet]. 2019 Jul. 3 [cited 2026 Nov. 3];6(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/1131